emergent biosolutions secures exclusive worldwide rights to valneva’s zika vaccine technology  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search see headlines for ebs view print version more from globenewswire emergent biosolutions secures exclusive worldwide rights to valneva’s zika vaccine technology emergent biosolutions to release second quarter  financial results and conduct a conference call on august   emergent biosolutions to acquire raxibacumab an fdaapproved anthrax monoclonal antibody from gsk referenced stocks ebs  rate it emergent biosolutions secures exclusive worldwide rights to valneva’s zika vaccine technology by globenewswire  july    pm edt vote up a a a emergent biosolutions secures exclusive worldwide rights to valnevas zika vaccine technology parties to collaborate through phase  clinical development  phase  trial expected to commence in late  or early  gaithersburg md july   globe newswire  emergent biosolutions inc nyseebs today announced a licensing agreement with valneva se for global exclusive rights to valnevas zika vaccine technology zikv emergent and valneva will codevelop zikvvla a highly purified inactivated vaccine candidate against the zika virus from preclinical development through completion of a phase  safety and immunogenicity clinical trial zikvvla which has shown to elicit functional antibody responses is based on valnevas established inactivated whole virus manufacturing platform on which its licensed japanese encephalitis vaccine was developed and produced emergent is focused on providing preparedness solutions to public health threats and emerging infectious diseases said adam havey executive vice president business operations of emergent biosolutions this commitment extends beyond acquiring revenuegenerating products and advancing our own products to aligning with partners such as valneva to develop innovative products that could potentially serve the needs of both government customers and the commercial market under the terms of the agreement emergent will pay valneva € million upfront and will get exclusive rights to use valnevas intellectual property and knowhow related to zika product development the companies are expected to enter into a technology transfer agreement at a later time to enable transfer of valnevas technology to emergents bayview manufacturing facility in baltimore maryland the companies plan to initiate the phase  trial in late  or early  and will share all costs until the availability of phase  data which is anticipated within six months from trial initiation emergent will have the option to continue the development arrangement with valneva for a milestone payment of € million upon availability of phase  data the agreement also provides valneva potential additional milestone payments of up to € million related to product development approval commercialization and product sales and future royalties on annual net sales emergent has product candidates in various stages of development that target emerging infectious diseases such as zika ebola dengue and influenza including a zika hyperimmune therapeutic being developed on the companys hyperimmune platform about emergent biosolutionsemergent biosolutions inc is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental intentional and naturally emerging public health threats through our work we envision protecting and enhancing  million lives with our products by  additional information about the company may be found at emergentbiosolutionscom follow us emergentbiosolu safe harbor statementthis press release includes forwardlooking statements within the meaning of the private securities litigation reform act of  any statements other than statements of historical fact including statements regarding our plans and prospects regarding zikvvla and any other statements containing the words believes expects anticipates intends plans estimates and similar expressions are forwardlooking statements these forwardlooking statements are based on our current intentions beliefs and expectations regarding future events we cannot guarantee that any forwardlooking statement will be accurate investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize actual results could differ materially from our expectations investors are therefore cautioned not to place undue reliance on any forwardlooking statement any forwardlooking statement speaks only as of the date of this press release and except as required by law we do not undertake to update any forwardlooking statement to reflect new information events or circumstances there are a number of important factors that could cause the companys actual results to differ materially from those indicated by such forwardlooking statements including the success of our planned preclinical studies and clinical trials of zikvvla the success of our planned technology transfer to our bayview manufacturing facility in baltimore maryland and our estimates regarding development expenses the foregoing sets forth many but not all of the factors that could cause actual results to differ from our expectations in any forwardlooking statement investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the sec when evaluating our forwardlooking statements investor contact robert g burrows vice president investor relations  burrowsrebsicom media contact lynn kieffer vice president corporate communications  kiefferlebsicom source emergent biosolutions inc this article appears in news headlines referenced stocks ebs latest news video pakistan pm nawaz sharif resigns af weekend events in west palm beach  login please enable javascript to view the comments powered by realtidbits related stocks articles subscribe booming commercial jet deliveries boost embraer   am wisdomtree falls short despite attracting more assets   am deckers gloomy outlook overshadows solid results   am closex signin existing nasdaqcom member log in here by signing into to the site using any of the thirdparty services above you agree to nasdaqcoms terms of use welcome back log in using your   account switch accounts highest rated articles of last week shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the mitel to acquire shoretel  quick facts miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results view all highest rated todays market activity nasdaq    ▼   djia    ▲   sp     ▼   data as of jul    pm try for free nasdaq livequotes platform view all upcoming earnings company expected report date aapl jul   odfl jul   fb jul   tsla aug   t jul   amzn jul   vz jul   ge jul   earnings calendar closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia   redirected from bioport jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view emergent biosolutions inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report emergent biosolutions inc  product pipeline review   published by global markets direct product code  published march   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license emergent biosolutions inc  product pipeline review   published march   content info  pages description summary global markets directs emergent biosolutions inc  product pipeline review   provides an overview of the emergent biosolutions incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by emergent biosolutions inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of emergent biosolutions inc the report provides overview of emergent biosolutions inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses emergent biosolutions incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features emergent biosolutions incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate emergent biosolutions incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for emergent biosolutions inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding emergent biosolutions incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures emergent biosolutions inc snapshot emergent biosolutions inc overview key information key facts emergent biosolutions inc  research and development overview key therapeutic areas emergent biosolutions inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities emergent biosolutions inc  pipeline products glance emergent biosolutions inc  late stage pipeline products filing rejectedwithdrawn productscombination treatment modalities emergent biosolutions inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities emergent biosolutions inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities emergent biosolutions inc  drug profiles coagulation factor ix recombinant product description mechanism of action rd progress av product description mechanism of action rd progress otlertuzumab product description mechanism of action rd progress previthrax product description mechanism of action rd progress es product description mechanism of action rd progress e product description mechanism of action rd progress antihemophilic factor recombinant product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress ev product description mechanism of action rd progress gc product description mechanism of action rd progress mvarsv product description mechanism of action rd progress mvahha product description mechanism of action rd progress recombinant protein to inhibit cd and cd for bcell lymphoma product description mechanism of action rd progress monoclonal antibody for ebola and marburg infections product description mechanism of action rd progress recombinant protein to target her and cd for cancer product description mechanism of action rd progress recombinant protein to target ron and cd for cancer product description mechanism of action rd progress vaccines for undisclosed indication product description mechanism of action rd progress emergent biosolutions inc  pipeline analysis emergent biosolutions inc  pipeline products by target emergent biosolutions inc  pipeline products by route of administration emergent biosolutions inc  pipeline products by molecule type emergent biosolutions inc  pipeline products by mechanism of action emergent biosolutions inc  recent pipeline updates emergent biosolutions inc  dormant projects emergent biosolutions inc  dormant projects emergent biosolutions inc  discontinued pipeline products discontinued pipeline product profiles anthrivig immune globulin leucotropin pep tst emergent biosolutions inc  company statement emergent biosolutions inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables emergent biosolutions inc key information emergent biosolutions inc key facts emergent biosolutions inc  pipeline by indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  partnered products in pipeline  emergent biosolutions inc  partnered products combination treatment modalities  emergent biosolutions inc  filing rejectedwithdrawn  emergent biosolutions inc  phase ii  emergent biosolutions inc  phase i  emergent biosolutions inc  preclinical  emergent biosolutions inc  discovery  emergent biosolutions inc  pipeline by target  emergent biosolutions inc  pipeline by route of administration  emergent biosolutions inc  pipeline by molecule type  emergent biosolutions inc  pipeline products by mechanism of action  emergent biosolutions inc  recent pipeline updates  emergent biosolutions inc  dormant developmental projects emergent biosolutions inc  discontinued pipeline products  emergent biosolutions inc other locations emergent biosolutions inc subsidiaries list of figures emergent biosolutions inc  pipeline by top  indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  pipeline by top  target  emergent biosolutions inc  pipeline by route of administration  emergent biosolutions inc  pipeline by molecule type  emergent biosolutions inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia   redirected from bioport jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia   redirected from bioport jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia   redirected from bioport jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info market report emergent biosolutions inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing emergent biosolutions inc  product pipeline review   may    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs emergent biosolutions inc  product pipeline review   provides an overview of the emergent biosolutions incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of emergent biosolutions incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasereport scopethe report provides brief overview of emergent biosolutions inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of emergent biosolutions incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the emergent biosolutions incs pipeline productsreasons to get this reportevaluate emergent biosolutions incs strategic position with total access to detailed information on its product pipelineassess the growth potential of emergent biosolutions inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the emergent biosolutions incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of emergent biosolutions inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of emergent biosolutions incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of emergent biosolutions inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contents list of tables list of figures emergent biosolutions inc snapshot emergent biosolutions inc overview key information key facts emergent biosolutions inc  research and development overview key therapeutic areas emergent biosolutions inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities emergent biosolutions inc  pipeline products glance emergent biosolutions inc  late stage pipeline products filing rejectedwithdrawn productscombination treatment modalities emergent biosolutions inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities emergent biosolutions inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities emergent biosolutions inc  drug profiles coagulation factor ix recombinant product description mechanism of action rd progress av product description mechanism of action rd progress otlertuzumab product description mechanism of action rd progress previthrax product description mechanism of action rd progress avpd product description mechanism of action rd progress es product description mechanism of action rd progress antihemophilic factor recombinant product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress ev product description mechanism of action rd progress gc product description mechanism of action rd progress monoclonal antibody to inhibit hemagglutinin for influenza product description mechanism of action rd progress mvarsv product description mechanism of action rd progress mvahha product description mechanism of action rd progress recombinant protein cytotoxic to cells expressing cd and cd for cancer product description mechanism of action rd progress recombinant protein to target her and cd for cancer product description mechanism of action rd progress recombinant protein to target ron and cd for cancer product description mechanism of action rd progress vaccines for undisclosed indication product description mechanism of action rd progress emergent biosolutions inc  pipeline analysis emergent biosolutions inc  pipeline products by target emergent biosolutions inc  pipeline products by route of administration emergent biosolutions inc  pipeline products by molecule type emergent biosolutions inc  pipeline products by mechanism of action emergent biosolutions inc  recent pipeline updates emergent biosolutions inc  dormant projects emergent biosolutions inc  discontinued pipeline products discontinued pipeline product profiles anthrivig immune globulin leucotropin pep tst emergent biosolutions inc  company statement emergent biosolutions inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesemergent biosolutions inc key information emergent biosolutions inc key facts emergent biosolutions inc  pipeline by indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  partnered products in pipeline  emergent biosolutions inc  partnered products combination treatment modalities  emergent biosolutions inc  filing rejectedwithdrawn  emergent biosolutions inc  phase ii  emergent biosolutions inc  phase i  emergent biosolutions inc  preclinical  emergent biosolutions inc  discovery  emergent biosolutions inc  pipeline by target  emergent biosolutions inc  pipeline by route of administration  emergent biosolutions inc  pipeline by molecule type  emergent biosolutions inc  pipeline products by mechanism of action  emergent biosolutions inc  recent pipeline updates  emergent biosolutions inc  dormant developmental projects emergent biosolutions inc  discontinued pipeline products  emergent biosolutions inc other locations emergent biosolutions inc subsidiaries list of figuresemergent biosolutions inc  pipeline by top  indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  pipeline by top  target  emergent biosolutions inc  pipeline by top  route of administration  emergent biosolutions inc  pipeline by top  molecule type  emergent biosolutions inc  pipeline products by top  mechanism of action   companies mentioned in this reportemergent biosolutions inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia   redirected from bioport jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view ubs group ag decreases position in emergent biosolutions inc ebs friday  july  about us contact info advertising latest news lowe wealth advisors llc has  position in newmont mining corporation nem imperial oil ltd usa imo analysts see  eps oxbow advisors llc takes position in teva pharmaceutical industries limited teva puerto rico votes to become st state of america main » ubs group ag decreases position in emergent biosolutions inc ebs ubs group ag decreases position in emergent biosolutions inc ebs  july  nyseebs have recently changed their ratings on the stock the algebris investments llp holds  shares with  value down from  last quarter consolidated edison i now has  billion valuation the stock declined  or  reaching  per shareabout  shares traded consolidated edison inc nyseed has risen  since july   and is uptrendingemergent biosolutions inc had its  rating reiterated by analysts at chardan capital about  shares traded or  up from the average the company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental intentional and naturally emerging public health threats one research analyst has rated the stock with a sell rating one has given a hold rating and four have assigned a buy rating to the companys stockon january  jp morgan kept the stock rating at overweight but moved up the price target from  to  the firm has hold rating given on monday august  by zacks the company was downgraded on thursday october  by raymond james the company was maintained on monday may  by ubs jerry jones backs ezekiel elliott says theres no evidence of domestic violence two more could be cornerback nolan carroll drunkendriving charge and linebacker damien wilson aggravated assault charges so what did it all boil down to sunday jones and the cowboys may be right in a legal sense analysts await regions financial corp nyserf to report earnings on july  before the open during the same quarter past year the company earned  earnings per share  were reported by beacon truinvestors sentiment increased to  in q  its up  from  in qseveral other hedge funds and other institutional investors also recently added to or reduced their stakes in ebs  funds opened positions while  raised stakes  million shares or  more from  million shares in q were reported it is positive as  investors sold cigna corporation shares while  reduced holdings state street corp accumulated  or m shares tcw gp stated it has  shares or  of all its holdings vanguard group has invested  in regions financial corp nyserf national bank  trust of nova scotia has  invested in consolidated edison inc covington inv advsrs holds  or  shares in its portfolio hall laurie j trustee holds  shares or  of its portfolio hauer jerome m sold  worth of stock or  shares bnp paribas arbitrage sa new yorkbased fund reported  sharesinvestors sentiment is  in  q its the same as in q ny uses the crumbling mta like a piggy bank de blasio hizzoner insisted the publictransit state of emergency declared recently by cuomo was not about the mta needing more money the press conference was over hes so tall she said emergent biosolutions inc has a one year low of  and a one year high of  emergent biosolutions earned a coverage optimism score of  on accerns scale foundry partners lc owns  shares smith asset mgmt lp has  shares for  of their portfolio investec asset management ltd reported  million shares stake ajo ltd partnership invested in  or  shares as of quarter end eqis capital management inc had bought  shares growing its holdings by  as of the last earnings report the eps was  and is expected to be  for the current year with  shares outstandingshares of emergent biosolutions inc earnest prtnrs lc reported  sharesemergent biosolutions nyseebs last issued its quarterly earnings data on thursday may th they expect  earnings per share up  or  from last years  per share ebss profit will be  million for  pe if the  eps becomes a reality next quarters eps is estimated at  with next years eps projected to be  creative planning increased its stake in emergent biosolutions by  in the second quarter therefore  are positive  emergent biosolutions inc was downgraded to  by analysts at thestreet the companys day moving average is  and its  day moving average is  after having  eps previously emergent biosolutions incs analysts see   eps growth the firm has outperform rating by wells fargo given on friday february  cowen  co maintained it with hold rating and  target in friday july  report bidaskclub raised shares of emergent biosolutions from a hold rating to a buy rating in a research note on saturday june th the rating was upgraded by zacks to hold on monday august  dodgers showing strong interest in yu darvish the rangers are not expected to give him a big offer at this time per buster olney of espn  on the season darvish has posted a  era and  strikeouttowalk ratio in  starts related articles manchester united beat real madrid in shambolic shootout jones lang lasalle nysejll earning somewhat negative news coverage report finds poles protest for th day over contentious judicial changes tom brady congratulated jordan spieth on his dramatic open win a potentially rabid squirrel is on the loose in prospect park rcmp calls off search for missing australian woman family acadia pharmaceuticals nasdaqacad given media sentiment score of  british open  updated leaderboard after round  job offers fly in for girl of  barred from selling lemonade browns agree with jabrill peppers to rookie deal share  previous jerry jones backs ezekiel elliott says theres no evidence of domestic violence next dodgers showing strong interest in yu darvish advertising more news russia did us election interference allegations cost russian ambassador his job is srk collaborating with diplo on a music video sensex hits alltime high nifty nears  level reliance industries leads gains tallgrass energy gp lp tegp eps estimated at  reliance jio added  million new subscribers last quarter vertex pharmaceuticals incorporated vrtx given buy rating at needham  company llc antero midstream partners lp co nyseam trading volume significantly lower nfl network snafu behind him fourstar wr jamarr chase picks florida ww grainger inc gww shares bought by schmidt pj investment management inc rock river closed as nearrecord flooding is expected govt hajj scheme flight operation begins will the white house bring back cameras piers morgan trolled virender sehwag on twitter scaramucci said to join white house as spicer reported to resign liverpool wait for southampton approval before van dijk talks copyright   healthcaremenu  all rights reserved emergent biosolutions  facebook facebookemail or phonepasswordforgot accountsign upenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook   data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel emergent biosolutions inc nyseebs files an k entry into a material definitive agreement  market exclusive sign in join home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps sign in welcomelog into your accountyour usernameyour password forgot your password sign up welcomeregister for an account your emailyour username a password will be emailed to you password recovery recover your passwordyour email search sign in  joinmy account orders sign inwelcome log into your accountyour usernameyour password forgot your password get helpcreate an account create an accountwelcome register for an accountyour emailyour username a password will be emailed to you password recoveryrecover your passwordyour email a password will be emailed to you market exclusive home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps home sec filings emergent biosolutions inc nyseebs files an k entry into a material definitive sec filings emergent biosolutions inc nyseebs files an k entry into a material definitive agreement byme staff k july    share on facebook tweet on twitter emergent biosolutions inc nyseebs files an k entry into a material definitive agreementitem entry into a material definitive agreement on july   emergent biosolutions inc entered into an asset purchase agreement with human genome sciences inc a delaware corporation hgs glaxosmithkline llc a delaware limited liability company gsk and collectively with hgs the seller to which emergent will acquire certain assets and liabilities of seller relating to sellers raxibacumab product for an upfront payment of  million and milestone payments of up to  million in the aggregate tied to the achievement of certain product sale and manufacturingrelated milestones raxibacumab is a monoclonal antibody approved by the food and drug administration for the treatment of adult and pediatric patients with inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or not appropriate the product has also been granted orphan drug market exclusivity in the united states until december  under the agreement upon the closing of the transaction emergent will  acquire among other assets raxibacumab including corresponding product rights regulatory approvals and intellectual property rights and  plan to assume an existing multiyear contract with the biomedical advanced research and development authority barda for the purchase and delivery of raxibacumab to the strategic national stockpile the completion of the transaction is subject to certain closing conditions including  expiration or termination of the applicable waiting period under the hartscottrodino antitrust improvements act of  as amended  receipt of consents under certain material contracts and  certain other customary conditions there is no financing condition to the closing of the transaction in connection with the closing of the transaction emergent will enter into various agreements with seller or its affiliates including  a prenovation agreement to which seller will subcontract to emergent the rights and obligations of seller under the barda contract until novation of the contract is effective to emergent following the closing of the transaction  a technical transfer agreement for up to a fouryear term under which seller will transfer the manufacturing process bulk and fillfinish related to raxibacumab to emergents facilities in baltimore maryland  a supply agreement under which seller will manufacture and deliver raxibacumab to barda on behalf of emergent for the duration of certain orders under the barda contract and  a transitional services agreement to which seller will perform certain services for emergent for a limited period of time following the closing of the transaction the agreement also contains certain termination rights for emergent and seller upon any termination of the agreement the agreement will become void and have no effect except that certain specified obligations of emergent and seller shall survive including their respective obligations concerning confidentiality and public announcements the foregoing description of the terms and conditions of the agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement filed herewith as exhibit  and incorporated herein by reference a copy of the agreement is attached as an exhibit hereto it is not intended to provide any other factual information about emergent or seller in particular the assertions embodied in the representations and warranties contained in the agreement are qualified by information in the disclosure schedules provided by seller to emergent in connection with the signing of the agreement or in filings of the parties with the securities and exchange commission these confidential disclosure schedules contain information that modifies qualifies and creates exceptions to the representations and warranties and certain covenants set forth in the agreement moreover certain representations warranties and covenants in the agreement were used for the purposes of allocating risk between emergent and the seller rather than establishing matters of fact or reflecting what investors may view as material accordingly the representations and warranties and covenants in the agreement or any descriptions thereof should not be relied on as a characterization of the actual state of facts about emergent or seller or their respective subsidiaries or affiliates additionally the representations warranties covenants conditions and other terms of the agreement may be subject to subsequent waiver or modification moreover information concerning the subject matter of the representations and warranties and covenants in the agreement may change after the date of the agreement which subsequent information may or may not be fully reflected in emergents or the sellers public disclosures item regulation fd disclosure on july   emergent issued a press release announcing entry into the asset purchase agreement with the seller which is filed as exhibit  hereto item financial statements and exhibits dexhibits exhibitno description  asset purchase agreement dated july   by and between human genome sciences inc glaxosmithkline llc and emergent biosolutions inc press release dated july    the schedules and exhibits to the asset purchase agreement have been omitted in accordance with item bof regulation sk a copy of any omitted schedule or exhibit will be furnished to the securities and exchange commission upon request  confidential treatment has been requested for certain portions of this exhibit to ruleb under the securities exchange act of  as amended which portions are omitted and filed separately with the sec to the requirements of the securities exchange act of  the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized emergent biosolutions inc dated july   by s robert g kramer sr name robert g kramer sr title executive vice president administration and chief financial officer exhibit index description  asset purchase agreement dated july   by and between human genome sciences inc glaxosmithkline llc and emergent biosolutions inc  press release dated july    the schedules and exhibits to the asset purchase agreement have been omitted in accordance with item bof regulation sk a copy of any omitted schedule or exhibit will be furnished to the securities and exchange commission upon request  confidential treatment has been requested for certain portions of this exhibit about emergent biosolutions inc nyseebs emergent biosolutions inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats the company develops manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases eid it also develops and commercializes therapeutics in areas of hematologyoncology transplantation infectious diseases and autoimmune disorders its two operating divisions include biodefense and biosciences the biodefense division is a pharmaceutical business focused on countermeasures that address public health threats including chemical biological radiological nuclear and explosives cbrne threats as well as eid the biosciences division is a pharmaceutical business focused on therapeutics in hematologyoncology with secondary on transplantation infectious disease and autoimmunity please enable javascript to view the comments powered by disqusan ad to help with our costs related articlesmore from author fcb financial holdings inc nysefcb files an k results of operations and financial condition genius brands international inc nasdaqgnus files an k submission of matters to a vote of security holders first bancorp nasdaqfbnc files an k results of operations and financial condition crestwood equity partners lp nyseceqp files an k departure of directors or certain officers election of directors appointment of certain officers compensatory arrangements of advanced micro devices inc nasdaqamd files an k results of operations and financial condition western gas equity partners lp nysewgp files an k results of operations and financial condition subscribe to our newsletter email  first namelast nameemail a word from the sponsor latest articles pingtan marine enterprise ltd nasdaqpme files an k results of operations and financial condition rayonier advanced materials inc nyseryam files an k financial statements and exhibits armstrong world industries inc nyseawi files an k submission of matters to a vote of security holders recent posts emergent biosolutions inc nyseebs files an k entry into a material definitive agreement fcb financial holdings inc nysefcb files an k results of operations and financial condition genius brands international inc nasdaqgnus files an k submission of matters to a vote of security holders analyst activity – fbr  co reiterates outperform on alphabet nasdaqgoogl quest diagnostics incorporated nysedgx reported earnings of  per share beating walls streets expectations sponsored editor picks here’s what just happened with neuroderm ltd nasdaqndrm july   biotech movers at both end of the space glaxosmithkline plc adr july   here’s what just happened with ironwood pharmaceuticals inc nasdaqirwd and aeterna july   popular posts this small nasdaq hidden gem may have a b drug july   weekly biotech report covering – opko health inc nyseopk intercept april   facebook inc – nasdaqfb might be moving away from its april   popular categorysec filingsanalyst ratingslsestockstech newsbiotech stocksstock market newssmall capsinsider trading about usmarket exclusive offers the latest financial news and analysis for selected us stocks and securities we are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions at market exclusive we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices market exclusive is not a registered investment brokerdealer the content on this site is for informational purposes only additionally the content on this site does not represent the views of market exclusive and is solely a representation of the authors who publish them before investing in any security you should do your own due diligence and consult with a registered broker or financial advisorcontact us email protectedfollow us sec filings stocks stock market news tech news biotech stocks featured small caps gold other news oil become a contributor about marketexclusivecom contributors advertise on market exclusive contact us  market exclusive  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view emergent biosolutions inc  product pipeline review      about us blog contact us faq  usd eur gbp usd ▼ usd eur gbp € eur  usd £ gbp rest of world us toll free  advanced price from €eurusd£gbp view pricing home  categories  company reports select a format  €eurusd£gbp single user electronic pdf  this is a single user license allowing one specific user access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp site license electronic pdf  this is a site license allowing all users within a given geographical location of your organisation access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp enterprisewide electronic pdf  this is an enterprise license allowing all employees within your organisation access to the product the report will be emailed to you the report is sent in pdf format  add to basket order by fax need a quote  our clients have a question email us view faqs recently viewed products partner of research and marketsvaccinating  children in  why choose research and markets worlds largest selection trusted by the best customer focused safe  secure i have only positive feedback to offer the research and markets team the service is perfect quick and effective read more mr pavel kalugin manager aurora emergent biosolutions inc  product pipeline review   id  company profile march   pages global markets direct emergent biosolutions inc description table of contents samples formats  of  login to access executive summary printer friendly printable pdf brochure send to a friend emergent biosolutions inc  product pipeline review  summary‘emergent biosolutions inc  product pipeline review  ’ provides an overview of the emergent biosolutions inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by emergent biosolutions inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projectsour report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basisthe report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantagenote certain sections in the report may be removed or altered based on the availability and relevance of datascope the report provides a snapshot of the pipeline therapeutic landscape of emergent biosolutions inc the report provides overview of emergent biosolutions inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses emergent biosolutions inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features emergent biosolutions inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projectsreasons to buy evaluate emergent biosolutions inc’s strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for emergent biosolutions inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding emergent biosolutions inc’s pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope show less read more note product cover images may vary from those shown  of  login to access executive summary printer friendly printable pdf brochure send to a friend list of tables list of figures emergent biosolutions inc snapshot emergent biosolutions inc overview key information key facts emergent biosolutions inc  research and development overview key therapeutic areas emergent biosolutions inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities emergent biosolutions inc  pipeline products glance emergent biosolutions inc  late stage pipeline products filing rejectedwithdrawn productscombination treatment modalities emergent biosolutions inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities emergent biosolutions inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities emergent biosolutions inc  drug profiles coagulation factor ix recombinant product description mechanism of action rd progress av product description mechanism of action rd progress otlertuzumab product description mechanism of action rd progress previthrax product description mechanism of action rd progress es product description mechanism of action rd progress e product description mechanism of action rd progress antihemophilic factor recombinant product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress ev product description mechanism of action rd progress gc product description mechanism of action rd progress mvarsv product description mechanism of action rd progress mvahha product description mechanism of action rd progress recombinant protein to inhibit cd and cd for bcell lymphoma product description mechanism of action rd progress monoclonal antibody for ebola and marburg infections product description mechanism of action rd progress recombinant protein to target her and cd for cancer product description mechanism of action rd progress recombinant protein to target ron and cd for cancer product description mechanism of action rd progress vaccines for undisclosed indication product description mechanism of action rd progress emergent biosolutions inc  pipeline analysis emergent biosolutions inc  pipeline products by target emergent biosolutions inc  pipeline products by route of administration emergent biosolutions inc  pipeline products by molecule type emergent biosolutions inc  pipeline products by mechanism of action emergent biosolutions inc  recent pipeline updates emergent biosolutions inc  dormant projects emergent biosolutions inc  dormant projects emergent biosolutions inc  discontinued pipeline products discontinued pipeline product profiles anthrivig immune globulin leucotropin pep tst emergent biosolutions inc  company statement emergent biosolutions inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesemergent biosolutions inc key information emergent biosolutions inc key facts emergent biosolutions inc  pipeline by indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  partnered products in pipeline  emergent biosolutions inc  partnered products combination treatment modalities  emergent biosolutions inc  filing rejectedwithdrawn  emergent biosolutions inc  phase ii  emergent biosolutions inc  phase i  emergent biosolutions inc  preclinical  emergent biosolutions inc  discovery  emergent biosolutions inc  pipeline by target  emergent biosolutions inc  pipeline by route of administration  emergent biosolutions inc  pipeline by molecule type  emergent biosolutions inc  pipeline products by mechanism of action  emergent biosolutions inc  recent pipeline updates  emergent biosolutions inc  dormant developmental projects emergent biosolutions inc  discontinued pipeline products  emergent biosolutions inc other locations emergent biosolutions inc subsidiaries list of figuresemergent biosolutions inc  pipeline by top  indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  pipeline by top  target  emergent biosolutions inc  pipeline by route of administration  emergent biosolutions inc  pipeline by molecule type  emergent biosolutions inc  pipeline products by top  mechanism of action  note product cover images may vary from those shown  of  loading  of  note product cover images may vary from those shown related products emergent biosolutions inc  product pipeline review    company profile may  from €eurusd£gbp emergent biosolutions inc ebs  financial and strategic swot analysis review  swot analysis march  from €eurusd£gbp emergent biosolutions inc company profile  business description strategies swot and financial analysis  swot analysis october  from €eurusd£gbp emergent biosolutions acquisition manual  mergers and acquisitions profiles july  €eurusd£gbp emergent biosolutions inc company profile  business strategies outlook statement business description products and services competitors employees updates swot and financials  company profile may  from €eurusd£gbp emergent biosolutions inc  mergers  acquisitions ma partnerships  alliances and investment report  mergers and acquisitions profiles june  from €eurusd£gbp ibio inc  product pipeline review    company profile august  from €eurusd£gbp emergent biosolutions inc  company profile  pages july  €eurusd£gbp emergent biosolutions inc  company profile july  €eurusd£gbp integrated biotherapeutics inc  product pipeline review    company profile february  from €eurusd£gbp close emergent biosolutions inc  product pipeline review   close ask a question required information product emergent biosolutions inc  product pipeline review   your question your contact details title mr mrs dr miss ms prof first name last name email address country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe phone number                                                                                                                                                                                                                                    we request your telephone number so we can contact you in the event we have difficulty reaching you via email we aim to respond to all questions on the same business day close send to a friend  required information friends details full name email address message to friend your contact details full name email address close request a quote please complete the below form and click send request to obtain a pdf quotation and order form this document will be available for immediate download and will also be emailed to you  required information your address address  address  address  city postalzip code country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe state your details title mr mrs dr miss ms prof first name last name organisation email address phone number                                                                                                                                                                                                                                    po number if applicable product format license format properties price single user electronic pdf the report will be emailed to you the report is sent in pdf format this is a single user license allowing one specific user access to the product €eurusd£gbp site license electronic pdf the report will be emailed to you the report is sent in pdf format this is a site license allowing all users within a given geographical location of your organisation access to the product €eurusd£gbp enterprisewide electronic pdf the report will be emailed to you the report is sent in pdf format this is an enterprise license allowing all employees within your organisation access to the product €eurusd£gbp  the price quoted above is only valid for  days please submit your order within that time frame to avail of this price as all prices are subject to change emergent biosolutions  wikipedia emergent biosolutions from wikipedia the free encyclopedia   redirected from bioport jump to navigation search emergent biosolutions type public company traded as nyse ebs sp  component founded  headquarters gaithersburg maryland key people daniel j abdunnabi ceo fuad elhibri executive chairman of the board of directors daniel j abdunnabi president and chief executive officer revenue us  million  operating income us  million  profit us  million  website official website footnotes  references  emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes among the companys notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the us food and drug administration fda the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer fuad elhibri the founder of the company and former ceo led the company since its founding as bioport inc until his retirement on april   elhibri continues to serve as the executive chairman of emergent biosolutions’ board of directors contents  biothrax  company history  leadership  financial information   activity and financial figures  rd and manufacturing operations  public affairs  see also  references  notes  external links biothraxedit further information anthrax vaccine anthrax vaccine adsorbed according to the us national library of medicine biothrax was first made available in  biothrax anthrax vaccine adsorbed a vaccine licensed by the us food and drug administration following a study by scientists from the centers for disease control and prevention on december   emergent received final fda licensing for use of biothrax five doses for intramuscular injection later in  emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years biothrax was approved for distribution in the united statesnot in citation given biothrax has received marketing approval in india singapore and germany the fda gave biothrax an orphan drug designation in april  the fda gives that status to drugs that are used to treat rare diseases biothrax is the only anthrax vaccine licensed by the fda as of april  emergent has sold over  million doses of biothrax to the us government three million us military personnel have received the biothrax vaccine the main buyer of biothrax is the us centers for disease control and prevention cdc the cdc buys biothrax for the strategic national stockpile sns the government uses the sns to protect the public in the event of a national emergency like a terrorist attack as of december  emergent has a  million contract with the cdc for biothrax the biothrax vaccines will go to the sns the contract will supply around  million doses of the vaccine additionally the biomedical advanced research and development authority barda released a notice of intent to purchase around  million of biothrax for the sns in  emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax on june   emergent announced that it had moved a step forward in the process the fda completed the preapproval phase of its inspection company historyedit acquisition history   antex biologics inc   microscience ltd   vivacs gmbh   a group of anthrax monoclonal antibodies from avanir pharmaceuticals   anthrax vaccine program patents and processes from vaxgen   trubion pharmaceuticals   healthcare protective products division of bracco diagnostics inc which includes rsdl decontamination lotion   cangene corporation emergent biosolutions was founded on september   under the name bioport and renamed emergent biosolutions in  at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan bioport purchased the facility and the rights to manufacture the vaccine for the us military after the  anthrax attacks following the terrorist attacks on september  bioport worked with the us government to supply anthrax countermeasures emergent became a publicly traded company in  with its stock trading on the new york stock exchange under the symbol ebs in june  emergent along with novartis and the texas am university system was selected by the us department of health and human services as one of the three centers for innovation in advanced development and manufacturing the publicprivate partnership granted emergent  million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics the purpose is to produce medical countermeasures in the event of a national pandemic emergents facility is located in maryland and the company expects the site to be operational by the year  on june   the us biomedical advanced research and development authority contracted with emergent biosolutions to develop a vaccine for the zika virus the contract is spread out over  months and is worth around  million the vaccine could reach stageone clinical trials by early  as of the end of june   countries and territories had reported transmission of the zika virus from mosquitoes emergent could become the first company to develop a vaccine for the virus in december  health canada approved the purchase of emergents new botulism antitoxin called botulism antitoxin heptavalent bat the cdc and public health agency of canada both identified botulism a type of food poisoning as a likely biological threat emergent already has a tenyear contract with the canadian military and national health service to supply bat that began in  emergent also provides bat to the us strategic national stockpile bat was first licensed in the us in  and is the only botulism antitoxin available in the us for naturallyoccurring cases of noninfant botulism on march   emergent said it signed a modification to its contract with barda to manufacture and store bulk drug substance for its botulism antitoxin bat the contract is valued at approximately  million for five years the contract modification was technical in nature it allows emergent to file and deliver the final drug product to the strategic national stockpile in the future soligenix inc and emergent agreed to establish a “commercially viable production technology” for the development of rivax a potential vaccine aimed to protect against ricin exposure currently there are no treatments for ricin poisoning that have been proven effective soligenix is a latestage biopharmaceutical company that specializes in the development of treatments for rare diseases a product of castor oil production the ricin toxin can be a useful biological weapon due to its extreme potency stability and accessibility the national institute of allergy and infectious diseases funded the development of rivax costing an estimated  million the organization also financially backed the contract between emergent and soligenix most of the work will be conducted in baltimore maryland at emergent’s manufacturing facility emergent is a member of the alliance for biosecurity a group of companies and organizations that work towards improving the ability to respond to biological threats with vaccines and other countermeasures leadershipedit the current president and ceo of emergent biosolutions is daniel j abdunnabi he has held the position since april   prior to that he was the president and chief operating officer he holds an mlt from georgetown university jd from the university of san diego and ba from the university of massachusetts amherst in addition to running emergent abdunnabi speaks publicly on matters related to national security for example on april   he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats in  abdunnabi organized a visit by former florida governor jeb bush to emergents lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the us against terrorist attacks abdunnabi sits on the board of directors at biohealth innovation a publicprivate partnership that helps bring biohealth products to the marketplace financial informationedit forbes recognized emergent as the top performing company in the state of maryland for the  fiscal year forbes tracked the return of every public company between from june   to june   emergent had a total return during that time period of  percent in  emergent had revenue of  million  activity and financial figuresedit according to zacks emergents acquisition of cangene made both of emergents divisions biosciences and biodefense stronger in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in  began collaborating on a prostate cancer drug called es as of january  the drug is in the preclinical stage in early january  emergent publicly released its preliminary financial totals for the  year the company saw an increase in revenue gaap net incomea and adjusted net income revenue amounted to between – million which is  higher than revenue earned in  gaap net income was between  and  million a  increase adjusted net income increased by  percent to between  and  million also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future for  emergent expects – million in sales in the first three months of  and between – million for the full year emergent sold more biothrax in  than in the previous year biothrax sales amounted to approximately  million according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in  the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips believes that emergents drug to treat hemophilia b called ixinity will also drive growth in  as of january   the fda was reviewing emergents application for ixinity approval key financial figures current as of january   are listed in the table measure header market capitalization  enterprise value  profit margin  operating margin  cash on hand  debt  debtequity ratio  rd and manufacturing operationsedit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases one of emergents medical countermeasure products is rsdl a lotion that clears and neutralizes chemical warfare agents the product is used in over  countries around the world rsdl is made of the chemicals dekon   butanedione monoxime dam according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins as of  emergent manufactures the following products biothrax anthrax vaccine adsorbed anthrasil anthrax immune globulin intravenous bat botulism antitoxin heptavalent vigiv cnj vaccinia immune globulin intravenous rsdl reactive skin decontamination lotion products in development include nuthrax anthrax vaccine in phase ii clinical trials expected to enroll patients in phase iii studies in  fluigiv seasonal influenza therapeutic in phase ii clinical trials uvb dengue therapeutic zikvig zika therapeutic gc burkholderia therapeutic filov panfilovirus therapeutic ebola marburg sudan virus public affairsedit emergent biosolutions was among many companies giving financial support to delegations at both major party political conventions in the summer of  the conventions used the contributions for receptions food and transportation but by law could not use contributions to fund campaigns for example emergent hosted a breakfast reception at the democratic national convention in philadelphia the company sent representatives to both conventions with the aim of specifically meeting with maryland delegates to educate the delegates about medical countermeasures emergent runs a charitable giving program called give corporate social responsibility the company has given money to the lansing michigan school district prominent donations and scholarships include  to lansing j w sexton high school for the purchase of equipment for the ap biology program  to sexton high school for engineering equipment and  to the lansing promise scholarship fund emergent is also a donor to the relentless tour an antibullying program that tries to raise awareness of autism and the problem of autistic children being bullied see alsoedit biological warfare portal biotechnology portal companies portal science portal anthrax attacks of  anthrax toxin anthrax vaccine immunization program biotechnology list of pharmaceutical companies list of vaccine topics pharmaceutical industry referencesedit  emergent biosolutions corporate governance emergent biosolutions retrieved  july    emergent biosolutions inc ebs yahoo finance retrieved  may    emergent biosolutions  key statistics yahoo finance retrieved  may    emergent biosolutions  income statement yahoo finance retrieved  may    emergent biosolutions  balance sheet yahoo finance retrieved  may    emergent solutions biospace dice holdings inc retrieved  may    ramstack tom  october  biosolutions posts healthy progress the washington times p c   emergent biosolutions inc google finance retrieved  may    contact us emergent biosolutions retrieved  may    a b lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  march    shapiro andy  may  md firm to buy protein sciences new haven register   emergent biosolutions ceo joins board of us chamber of commerce the washington business journal  june  retrieved  march    overly steven  december  emergent ceo to step down in  the washington post retrieved  march    eckert barton  december  emergent biosolutions fuad elhibri to retire as ceo the washington business journal retrieved  march    kevin james shay  march  emergents fuad elhibri an entrepreneur at heart gazette retrieved  march    meyer weiss martin weiss peter d weiss joseph b november  anthrax vaccine and public health policy american journal of public health american public health association   – issn  pmc   pmid  doiajph   echols tucker  july  emergent biosolutions wins m hhs contract washington business journal   lauerman john  september  emergents anthrax vaccine effective with fewer doses in study bloomberg retrieved  july    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news december   retrieved august    emergent biosolutions gets fda nod for anthrax vaccine supplemental bla  update rtt news  december  retrieved  july    emergent biosolutions receives paulehrlichinstitut approval to market biothrax in germany yahoo finance press release july   retrieved august    clabaugh jeff  june  emergent gets entry to singapore washington business journal retrieved  july    local briefing the washington post  february  retrieved  july    a b c bryan cohen  april  emergent biosolutions’ biothrax receives orphan drug designation for pep bioprepwatch chicago illinois retrieved  may    a b emergent biosolutions receives orphan drug designation for biothrax for postexposure prophylaxis of anthrax disease marketwatchcom wall street journal dow jones  company  april  retrieved  may    a b c propthink p  emergent biosolutions is building an enviable biodefense portfolio seeking alpha retrieved  may    emergent biosolutions secures  mln contract to supply anthrax vaccines to strategic national stockpile homeland preparedness news  retrieved    lovelace jr berkeley  emergent biosolutions moves closer to facility approval for anthrax vaccine cnbc retrieved    tinder paul  november  emergent biosolutions appoints jackson as chief scientific officer vaccine news daily retrieved  april    emergent acquires vaccine company biotech patent news  june  issn    emergent biosolutions mit verstärkter präsenz in deutschland bionitycom in german bionity august   retrieved  april    avanir divests anthrax mab program to emergent biosolutions in deal worth m genetic engineering  biotechnology news  march  retrieved  october    vaxgen sells anthrax vaccine candidate to emergent biosolutions forbes thomson reuters  may  retrieved  july    vaxgen wraps up sale of anthrax assets san francisco business times  may  retrieved  july    emergent biosolutions completes acquisition of trubion pharmaceuticals the street  october  retrieved  april    cohen bryan  august  emergent biosolutions closes on acquisition of bracco diagnostics division vaccine news daily retrieved  may    emergent biosolutions closes on its acquisition of healthcare protective products division from bracco diagnostics inc yahoo finance  august  retrieved  may    cangene receives court approval of plan of arrangement for acquisition by emergent biosolutions wall street journal  retrieved   overly steven emergent biosolutions pays m to acquire life sciences firm cangene corp the washington post  retrieved   emergent biosolutions inc ebsnew york company description bloomberg businessweek retrieved  september    lansing laboratory may begin anthrax vaccine shipments the michigan daily  january  retrieved  april    williams thomas d  may  shays pentagon acted inappropriately the hartford courant retrieved  april    a b history emergent biosolutions retrieved  may    emergent licenses flu vaccine for new federal biodefense center gazettenet  january  retrieved  january    a b sievers lisa  april  first of three pandemic manufacturing sites could be ready by  chicago illinois retrieved  may    a b leong tracey  md company to develop earlystage zika vaccine cbsbaltimore retrieved    a b emergent biosolutions receives barda order to develop manufacture zika vaccine homeland preparedness news  retrieved    gregg aaron  emergent biosolutions wins contract to develop zika vaccine washington post retrieved    emergent biosolutions receives health canada approval for botulism antitoxin investorsemergentbiosolutionscom emergent biosolutions  retrieved    health canada approves emergent biosolutions’ botulism antitoxin homeland preparedness news  retrieved    a b emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxin emergent biosolutions  retrieved    soligenix emergent biosolutions extend development agreement for rivax drug substance protein antigen homeland preparedness news  retrieved    our members alliance for biosecurity retrieved    our mission alliance for biosecurity retrieved    executive profile daniel j abdunnabi bloomberg retrieved    corporate governance  biography  emergent investorsemergentbiosolutionscom retrieved    blue ribbon study panel on biodefense response and readiness cspanorg retrieved    miller faith jeb bush makes stop in lansing wilx nbc  retrieved    biohealth innovation inc bolsters board of directors with new members from emergent biosolutions and sr one  the business journals the business journals retrieved    borowski jaclyn  forbes says this is the bestperforming company in maryland baltimore business journal retrieved    a b emergent biosolutions provides preliminary  results  january    zackscom zacks chicago il zacks investment research  january  retrieved  january    a b burrows robert schmitt tracey  january  emergent biosolutions announces preliminary  financial results and provides  financial outlook nasdaq stock market  stock quotes  stock exchange news  nasdaqcom press release gaithersburg md emergent biosolutions globenewswire retrieved  january    guidance investopedia investopedia llc retrieved  january    the motley fool inc company profile  yahoo finance yahoo finance retrieved  january    orelli brian  november  emergent biosolutions inc busts through guidance sort of the motley fool the motley fool retrieved  january    ebs key statistics emergent biosolutions inc com stock yahoo finance  january  retrieved  january    emergent biosolutions secures orphan drug designation for its investigational monoclonal antibody for the treatment of inhalation anthrax health  beauty closeup  november    httpwwwrsdlcomchemicaldecontaminationprotectionfirstresponders  httpschemmnlmnihgovcountermeasurersdlhtm  httpsemergentbiosolutionscomproducts  httpsemergentbiosolutionscompipeline  fritze john  state issues money follow delegates to conventions the baltimore sun retrieved    lansing students get ap credits thanks to emergent biosolutions wlns channel  cbs lansing michigan  march  retrieved  may    a b lavey kathleen  october  k gift will pay for science scholarships in lansing lansing state journal retrieved  october    antibullying relentless tour to visit lansing area fox  news  march  retrieved  may   notesedit  the nasdaq source includes a statement regarding the reconciliation of gaap to nongaap net income and cites securities and exchange commission rules the full statement appears under the header iii reconciliation of gaap to nongaap net income in the source text  external linksedit official website food and drug administration license for biothrax retrieved from httpsenwikipediaorgwindexphptitleemergentbiosolutionsoldid categories companies listed on the new york stock exchangebiotechnology companies of the united statespharmaceutical companies of the united statespharmaceutical companies established in biotechnology companies established in  establishments in marylandhealth care companies based in marylandhidden categories cs germanlanguage sources dearticles which use infobox templates with no data rowsall articles with failed verificationarticles with failed verification from november pages with timeline metadataarticles prone to spam from october  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages nederlands edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view products for biological and chemical threats skip to main content close menu back to top close by using this site you agree to our privacy policy  close search toggle menu we develop manufacture and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases products biological threats biological agents are naturally occurring toxins or organisms that can result in illness or death to humans animals and crops exposure to biological pathogens can result from an intentional biological attack an accidental release of a biological agent or a natural incident our marketed products biothrax® anthrax vaccine adsorbed us prescribing information germany information singapore information anthrasiltm anthrax immune globulin intravenous human us prescribing information important information for healthcare providers july  important information for healthcare providers september  bat® botulism antitoxin heptavalent a b c d e f g  equine us prescribing information vigiv cnj® vaccinia immune globulin intravenous human vigiv us prescribing information biological threats biological agents are naturally occurring toxins or organisms that can result in illness or death to humans animals and crops exposure to biological pathogens can result from an intentional biological attack an accidental release of a biological agent or a natural incident our marketed products biothrax® anthrax vaccine adsorbed us prescribing information germany information singapore information anthrasiltm anthrax immune globulin intravenous human us prescribing information important information for healthcare providers july  important information for healthcare providers september  bat® botulism antitoxin heptavalent a b c d e f g  equine us prescribing information vigiv cnj® vaccinia immune globulin intravenous human vigiv us prescribing information biological threats biological agents are naturally occurring toxins or organisms that can result in illness or death to humans animals and crops exposure to biological pathogens can result from an intentional biological attack an accidental release of a biological agent or a natural incident our marketed products biothrax® anthrax vaccine adsorbed us prescribing information germany information singapore information anthrasiltm anthrax immune globulin intravenous human us prescribing information important information for healthcare providers july  important information for healthcare providers september  bat® botulism antitoxin heptavalent a b c d e f g  equine us prescribing information vigiv cnj® vaccinia immune globulin intravenous human vigiv us prescribing information chemical threats chemical agents are nonliving toxic products such as vapors gases aerosols liquids and solids that can cause serious harm or death to those exposed chemical agents can be released accidentally—for example in a laboratory incident or a pipeline leak—or intentionally our marketed products rsdl® reactive skin decontamination lotion kit chemical threats chemical agents are nonliving toxic products such as vapors gases aerosols liquids and solids that can cause serious harm or death to those exposed chemical agents can be released accidentally—for example in a laboratory incident or a pipeline leak—or intentionally our marketed products rsdl® reactive skin decontamination lotion kit chemical threats chemical agents are nonliving toxic products such as vapors gases aerosols liquids and solids that can cause serious harm or death to those exposed chemical agents can be released accidentally—for example in a laboratory incident or a pipeline leak—or intentionally our marketed products rsdl® reactive skin decontamination lotion kit emergent biosolutions  global specialty life sciences company skip to main content close menu close by using this site you agree to our privacy policy  close search toggle menu protecting you from public health threats our mission is to protect and enhance life watch our overview video emergent biosolutions prepare prevent protect we make medical countermeasures that address natural accidental and intentional public health threats our products target biological and chemical threats as well as emerging infectious diseases  strengthening our anthrax franchise emergent biosolutions to acquire raxibacumab from glaxosmithkline read the full press release expanding our portfolio of medical countermeasures emergent biosolutions to acquire acam vaccine business from sanofi read the full press release biothrax the only fda licensed anthrax vaccine hhs issues contract actions worth up to  billion in biothrax deliveries to the strategic national stockpile read the full press release nuthrax our next generation anthrax vaccine barda awards contract for advanced development and delivery of nuthrax valued at up to  billion read the full press release home explore more stories scroll down responsibility  emergent biosolutions skip to main content close menu back to top close by using this site you agree to our privacy policy  close search toggle menu building a healthier and safer world is a social responsibility mission that we take seriously  responsibility our corporate social responsibility efforts are a key part of our mission to protect and enhance life for millions around the world view online report download report  where we direct our corporate social responsibility efforts advancing global health  we take an innovative approach to improve the health and wellbeing of those in need both globally and in our communities  protecting those that protect us  we partner with organizations committed to enhancing the health and wellbeing of active military veterans first responders and their families  educating tomorrow’s scientific leaders  we support stem and public health education programs that cultivate promising young scientists and provide the means to start or continue their higher education  improving communities  we support nonprofit organizations within the communities where our employees live and work  our corporate social responsibility efforts are a key part of our mission to protect and enhance life for millions around the world view online report download report  where we direct our corporate social responsibility efforts advancing global health  we take an innovative approach to improve the health and wellbeing of those in need both globally and in our communities  protecting those that protect us  we partner with organizations committed to enhancing the health and wellbeing of active military veterans first responders and their families  educating tomorrow’s scientific leaders  we support stem and public health education programs that cultivate promising young scientists and provide the means to start or continue their higher education  improving communities  we support nonprofit organizations within the communities where our employees live and work  our corporate social responsibility efforts are a key part of our mission to protect and enhance life for millions around the world view online report download report  where we direct our corporate social responsibility efforts advancing global health  we take an innovative approach to improve the health and wellbeing of those in need both globally and in our communities  protecting those that protect us  we partner with organizations committed to enhancing the health and wellbeing of active military veterans first responders and their families  educating tomorrow’s scientific leaders  we support stem and public health education programs that cultivate promising young scientists and provide the means to start or continue their higher education  improving communities  we support nonprofit organizations within the communities where our employees live and work  we support philanthropic endeavors and activities that align with our corporate mission and goals   recent activities atlas college  career readiness symposiumadvancing tomorrow’s leaders in stem atlas is a college and career readiness symposium that… more children’s hospital foundation manitoba the children’s hospital foundation of manitoba is dedicated to ensuring that every child treated… more siloam mission winnipegsince  siloam mission has provided meals clothing and hope services to winnipeg’s poor… more more stories watch video we support philanthropic endeavors and activities that align with our corporate mission and goals   recent activities atlas college  career readiness symposiumadvancing tomorrow’s leaders in stem atlas is a college and career readiness symposium that… more children’s hospital foundation manitoba the children’s hospital foundation of manitoba is dedicated to ensuring that every child treated… more siloam mission winnipegsince  siloam mission has provided meals clothing and hope services to winnipeg’s poor… more more stories we support philanthropic endeavors and activities that align with our corporate mission and goals   recent activities atlas college  career readiness symposiumadvancing tomorrow’s leaders in stem atlas is a college and career readiness symposium that… more children’s hospital foundation manitoba the children’s hospital foundation of manitoba is dedicated to ensuring that every child treated… more siloam mission winnipegsince  siloam mission has provided meals clothing and hope services to winnipeg’s poor… more more stories educating tomorrows scientists advancing global health protecting those who protect us improving communities we continually work to safeguard the environment and health of the communities in which we live and work   recent activities adoptahighway and park cleanupthe adoptahighway program encourages volunteers to keep a section of a highway free from… more woldumar service daywoldumar nature center located in lansing michigan attracts more than  visitors a year… more more stories we continually work to safeguard the environment and health of the communities in which we live and work   recent activities adoptahighway and park cleanupthe adoptahighway program encourages volunteers to keep a section of a highway free from… more woldumar service daywoldumar nature center located in lansing michigan attracts more than  visitors a year… more more stories we continually work to safeguard the environment and health of the communities in which we live and work   recent activities adoptahighway and park cleanupthe adoptahighway program encourages volunteers to keep a section of a highway free from… more woldumar service daywoldumar nature center located in lansing michigan attracts more than  visitors a year… more more stories as part of our mission to protect and enhance life we are committed to conducting business operations in a safe and sustainable manner and working in our communities to improve the environment for all  business operations through our environmental policies we maintain compliance with applicable environmental laws regulations and other requirements to conserve natural resources and protect communities having completed a carbon footprint assessment of our global operations we are seeking additional ways to reduce our impact on the environment for current and future generations our corporate governance principles and practices are built on a foundation of openness integrity and accountability these are the principles that guide emergent every day governance products for biological and chemical threats skip to main content close menu back to top close by using this site you agree to our privacy policy  close search toggle menu we develop manufacture and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases products biological threats biological agents are naturally occurring toxins or organisms that can result in illness or death to humans animals and crops exposure to biological pathogens can result from an intentional biological attack an accidental release of a biological agent or a natural incident our marketed products biothrax® anthrax vaccine adsorbed us prescribing information germany information singapore information anthrasiltm anthrax immune globulin intravenous human us prescribing information important information for healthcare providers july  important information for healthcare providers september  bat® botulism antitoxin heptavalent a b c d e f g  equine us prescribing information vigiv cnj® vaccinia immune globulin intravenous human vigiv us prescribing information biological threats biological agents are naturally occurring toxins or organisms that can result in illness or death to humans animals and crops exposure to biological pathogens can result from an intentional biological attack an accidental release of a biological agent or a natural incident our marketed products biothrax® anthrax vaccine adsorbed us prescribing information germany information singapore information anthrasiltm anthrax immune globulin intravenous human us prescribing information important information for healthcare providers july  important information for healthcare providers september  bat® botulism antitoxin heptavalent a b c d e f g  equine us prescribing information vigiv cnj® vaccinia immune globulin intravenous human vigiv us prescribing information biological threats biological agents are naturally occurring toxins or organisms that can result in illness or death to humans animals and crops exposure to biological pathogens can result from an intentional biological attack an accidental release of a biological agent or a natural incident our marketed products biothrax® anthrax vaccine adsorbed us prescribing information germany information singapore information anthrasiltm anthrax immune globulin intravenous human us prescribing information important information for healthcare providers july  important information for healthcare providers september  bat® botulism antitoxin heptavalent a b c d e f g  equine us prescribing information vigiv cnj® vaccinia immune globulin intravenous human vigiv us prescribing information chemical threats chemical agents are nonliving toxic products such as vapors gases aerosols liquids and solids that can cause serious harm or death to those exposed chemical agents can be released accidentally—for example in a laboratory incident or a pipeline leak—or intentionally our marketed products rsdl® reactive skin decontamination lotion kit chemical threats chemical agents are nonliving toxic products such as vapors gases aerosols liquids and solids that can cause serious harm or death to those exposed chemical agents can be released accidentally—for example in a laboratory incident or a pipeline leak—or intentionally our marketed products rsdl® reactive skin decontamination lotion kit chemical threats chemical agents are nonliving toxic products such as vapors gases aerosols liquids and solids that can cause serious harm or death to those exposed chemical agents can be released accidentally—for example in a laboratory incident or a pipeline leak—or intentionally our marketed products rsdl® reactive skin decontamination lotion kit careers  emergent biosolutions skip to main content close menu back to top close by using this site you agree to our privacy policy  close search toggle menu emergent values the diversity each employee brings to their role and their contributions to helping us achieve our mission−to protect and enhance life  careers meetourpeople nadines story  jills story  larrys story  lisas story  yuefengs story  we strive to create an environment that is professionally and personally rewarding by offering challenging work and projects for individual and team contribution and opportunities for professional and personal development  we recognize the need for ongoing skill enhancement and support continued learning through onthejob assignments training programs tuition assistance professional memberships and professional conference attendance we value talent develop employees and offer promotional opportunities so our staff can achieve personal and professional growth we are a growing organization with a wide variety of scientific technical and professional career opportunities in the following areas  business development finance human resource information technology it legal affairs  compliance manufacturing operations marketing  sales medical affairs product development project management clinical operations facilities  engineering process  analytical development regulatory affairs quality assurance quality control contract manufacturing communications public affairs innovation office science  technology watch video our culture and core values  we live our core values every day through the work we do together  we believe in our mission and it drives our actions our five core values are  we respect each other  we deliver on our commitments  we empower our employees  we communicate openly  we pursue innovation  we also have fun here are a few examples of events that take place across our sites bring your child to work day cuatro de mayo summer picnic  zoo night golf tournament family movie night curling event sport event viewings in the ecafe elympics winter party holiday sweaters for hunger our culture and core values  we live our core values every day through the work we do together  we believe in our mission and it drives our actions our five core values are  we respect each other  we deliver on our commitments  we empower our employees  we communicate openly  we pursue innovation  we also have fun here are a few examples of events that take place across our sites bring your child to work day cuatro de mayo summer picnic  zoo night golf tournament family movie night curling event sport event viewings in the ecafe elympics winter party holiday sweaters for hunger our culture and core values  we live our core values every day through the work we do together  we believe in our mission and it drives our actions our five core values are  we respect each other  we deliver on our commitments  we empower our employees  we communicate openly  we pursue innovation  we also have fun here are a few examples of events that take place across our sites bring your child to work day cuatro de mayo summer picnic  zoo night golf tournament family movie night curling event sport event viewings in the ecafe elympics winter party holiday sweaters for hunger diversity  diversity and inclusion are an integral part of our culture we are committed to attracting developing and retaining the best diverse talent diversity fuels our business growth it drives innovation in the products and services we develop in the way we solve problems and in the way we serve the needs of an increasingly global and diverse customer and partner base we are committed to welcoming respecting and celebrating the unique attributes of our employees and communities we recognize the value that diversity contributes to our global organization and the competitive advantage we can maintain by having a broad range of talents perspectives and ideas with a commitment to continuously improving our business we ensure every employee applicant vendor and shareholder is treated fairly and equitably and we respect the attributes they offer examples of such attributes may include race religion color gender including pregnancy age marital status national origin disability militaryveteran status sexual orientation gender identity and any characteristics protected by local state provincial and federal law   for our employees we recruit hire train and promote qualified employees with diverse attributes we recognize and value the importance of our employees diverse attributes we provide an inclusive and collaborative environment to encourage employee input and ideas for our communities we positively contribute to the communities where we work and live we promote education and wellness we support diverse programs and organizations through internships sponsorships and volunteer activities emergent biosolutions  protect and enhance life skip to main content close menu back to top close by using this site you agree to our privacy policy  close search toggle menu about us ciadm expansion unveiling emergent biosolutions unveils its expanded ciadm in baltimore  learn more maryland tech councils ceo of the year dan abdunnabi wins maryland tech councils ceo of the year award  learn more biothrax® procurement emergent biosolutions awarded  million barda contract for biothrax deliveries to the strategic national stockpile  learn more viral hemorrhagic fever therapeutics emergent biosolutions receives barda task order valued at up to  million to develop viral hemorrhagic fever therapeutics  learn more canada approves bat® health canada approved emergent biosolutions new drug submission for botulism antitoxin  learn more dr kathryn c zoon emergent appoints dr kathryn c zoon to board of directors  learn more follow ebsi tweets by emergentbiosolu minimum  minute delaydata provided by thomson reuters refresh   prepare prevent protect learn how emergent is working to address serious public health threats   protecting you from public health threats our vision protecting and enhancing  million lives by  focuses our energy to improve the quality of life for millions of individuals around the world giving them the opportunity to experience the fullness of life  our drive towards this vision informs all of our actions—whether it is our approach to product development manufacturing encouraging employee health and wellness or giving back to the community—we strive every day to achieve this shared goal our vision protecting and enhancing  million lives by  focuses our energy to improve the quality of life for millions of individuals around the world giving them the opportunity to experience the fullness of life  our drive towards this vision informs all of our actions—whether it is our approach to product development manufacturing encouraging employee health and wellness or giving back to the community—we strive every day to achieve this shared goal our vision protecting and enhancing  million lives by  focuses our energy to improve the quality of life for millions of individuals around the world giving them the opportunity to experience the fullness of life  our drive towards this vision informs all of our actions—whether it is our approach to product development manufacturing encouraging employee health and wellness or giving back to the community—we strive every day to achieve this shared goal innovation unlocking our full potential powering our mindset advancing our mission innovation by employees at all levels is the key to achieving our full potential as individuals and as an organization we embrace the mindset that we are never done never satisfied never standing still innovation is the call to go higher faster and farther in our mission to protect and enhance life learn more about our innovation innovation unlocking our full potential powering our mindset advancing our mission innovation by employees at all levels is the key to achieving our full potential as individuals and as an organization we embrace the mindset that we are never done never satisfied never standing still innovation is the call to go higher faster and farther in our mission to protect and enhance life innovation unlocking our full potential powering our mindset advancing our mission innovation by employees at all levels is the key to achieving our full potential as individuals and as an organization we embrace the mindset that we are never done never satisfied never standing still innovation is the call to go higher faster and farther in our mission to protect and enhance life learn more about our innovation   history timeline under the leadership of daniel j abdunnabi the management team oversees the business operations of emergent meeting regularly these company leaders provide the strategic direction necessary to achieve our corporate goals management team under the leadership of daniel j abdunnabi the management team oversees the business operations of emergent meeting regularly these company leaders provide the strategic direction necessary to achieve our corporate goals under the leadership of daniel j abdunnabi the management team oversees the business operations of emergent meeting regularly these company leaders provide the strategic direction necessary to achieve our corporate goals management team the principal responsibility of the board of directors is to oversee the management of emergent in order to serve the best interests of the company and its stockholders the directors review and approve fundamental operating financial and other corporate plans strategies and objectives additionally the directors provide advice and assistance to the companys senior executives our board of directors the principal responsibility of the board of directors is to oversee the management of emergent in order to serve the best interests of the company and its stockholders the directors review and approve fundamental operating financial and other corporate plans strategies and objectives additionally the directors provide advice and assistance to the companys senior executives our board of directors the principal responsibility of the board of directors is to oversee the management of emergent in order to serve the best interests of the company and its stockholders the directors review and approve fundamental operating financial and other corporate plans strategies and objectives additionally the directors provide advice and assistance to the companys senior executives where you can find us contact us pipeline  emergent biosolutions skip to main content close menu back to top close by using this site you agree to our privacy policy  close search toggle menu emergents approach is to achieve balance in the products that we develop through a pipeline comprising innovative vaccines and therapeutics that target diseases worldwide pipeline pre clinical phase  phase  phase  nuthrax™anthrax vaccine candidate anthrax vaccine adsorbed with cpg  adjuvant phase  study first subject enrollment targeted for nuthrax™ anthrax vaccine adsorbed with cpg  adjuvant is being studied for use as a third generation anthrax vaccine this candidate consists of biothrax® anthrax vaccine adsorbed in combination with a novel immunostimulatory compound cpg    active clinical trials no active clinical trials completed clinical trials a phase  safety and immunogenicity study for an anthrax vaccine using  schedules and two dose levels safety tolerability and immunogenicity study of av anthrax vaccine in healthy adults        fluigivseasonal influenza therapeutic candidate hyperimmune platform phase  study first subject enrollment targeted for       uvbdengue therapeutic candidate broad spectrum antiviral phase b study initiated february uvb is an antiviral iminosugar being studied to treat dengue virus infections in addition future clinical activities on this compound are planned for influenza this product candidate has a mechanism of action that inhibits a host glycosylation pathway resulting in misfolded viral glycoproteins and subsequently leading to reduced viral infectivity active clinical trials safety and pharmacokinetics of uvb solution administered orally as multiple ascending doses to healthy subjects completed clinical trials study to determine the safety tolerability and pharmacokinetics of uvb solution administered orally in healthy subjects uv     zikvigzika therapeutic candidate hyperimmune platform phase  study first subject enrollment targeted for     gcburkholderia therapeutic candidate broad spectrum antibioticgc is the lead candidate based on emergents ev series of broad spectrum antibiotics these compounds have a novel oxoquinolizine antibacterial backbone showing activity against quinoloneresistant bacterial strains such as burkholderia pseudomallei   filovpanfilovirus therapeutic candidate ebola marburg sudan hyperimmune platform monoclonal antibody   clinical trials resources to learn more about clinical trails visit the websites below these sites are maintained by clinicaltrialsgov a webbased resource that provides patients their family members health care professionals researchers and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions clinicaltrialsgov is maintained by the national library of medicine at the national institutes of health understanding clinical trials glossary of clinical trials terms emergent biosolutions inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports emergent biosolutions inc  product pipeline review   emergent biosolutions inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports emergent biosolutions inc  product pipeline review  summaryglobal markets direct’s ‘emergent biosolutions inc  product pipeline review  ’ provides an overview of the emergent biosolutions inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of emergent biosolutions inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of emergent biosolutions inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of emergent biosolutions inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the emergent biosolutions inc’s pipeline productsreasons to buy evaluate emergent biosolutions inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of emergent biosolutions inc in its therapy areas of focus identify new drug targets and therapeutic classes in the emergent biosolutions inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of emergent biosolutions inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of emergent biosolutions inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of emergent biosolutions inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures emergent biosolutions inc snapshot emergent biosolutions inc overview key information key facts emergent biosolutions inc  research and development overview key therapeutic areas emergent biosolutions inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities emergent biosolutions inc  pipeline products glance emergent biosolutions inc  late stage pipeline products filing rejectedwithdrawn productscombination treatment modalities phase iii productscombination treatment modalities emergent biosolutions inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities emergent biosolutions inc  early stage pipeline products preclinical productscombination treatment modalities emergent biosolutions inc  drug profiles trenonacog alfa product description mechanism of action rd progress np product description mechanism of action rd progress av product description mechanism of action rd progress otlertuzumab product description mechanism of action rd progress previthrax product description mechanism of action rd progress avpd product description mechanism of action rd progress anticd x anticd product description mechanism of action rd progress antihha mab product description mechanism of action rd progress antiher x anticd product description mechanism of action rd progress antiron x anticd product description mechanism of action rd progress ctla x monoil product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress es product description mechanism of action rd progress ib product description mechanism of action rd progress mvahha product description mechanism of action rd progress mvarsv product description mechanism of action rd progress recombinant botulinum vaccine product description mechanism of action rd progress tnfr x a product description mechanism of action rd progress tnfr x tweakr product description mechanism of action rd progress emergent biosolutions inc  pipeline analysis emergent biosolutions inc  pipeline products by target emergent biosolutions inc  pipeline products by route of administration emergent biosolutions inc  pipeline products by molecule type emergent biosolutions inc  pipeline products by mechanism of action emergent biosolutions inc  recent pipeline updates emergent biosolutions inc  dormant projects emergent biosolutions inc  discontinued pipeline products discontinued pipeline product profiles immune globulin leucotropin pep tst emergent biosolutions inc  company statement emergent biosolutions inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesemergent biosolutions inc key information emergent biosolutions inc key facts emergent biosolutions inc  pipeline by indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  partnered products in pipeline  emergent biosolutions inc  partnered products combination treatment modalities  emergent biosolutions inc  filing rejectedwithdrawn  emergent biosolutions inc  phase iii  emergent biosolutions inc  phase ii  emergent biosolutions inc  phase i  emergent biosolutions inc  preclinical  emergent biosolutions inc  pipeline by target  emergent biosolutions inc  pipeline by route of administration  emergent biosolutions inc  pipeline by molecule type  emergent biosolutions inc  pipeline products by mechanism of action  emergent biosolutions inc  recent pipeline updates  emergent biosolutions inc  dormant developmental projects emergent biosolutions inc  discontinued pipeline products  emergent biosolutions inc other locations emergent biosolutions inc subsidiaries list of figuresemergent biosolutions inc  pipeline by top  indication  emergent biosolutions inc  pipeline by stage of development  emergent biosolutions inc  monotherapy products in pipeline  emergent biosolutions inc  pipeline by top  target  emergent biosolutions inc  pipeline by top  route of administration  emergent biosolutions inc  pipeline by top  molecule type  emergent biosolutions inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send emergent biosolutions to acquire acam® business from sanofi nyseebs english français register sign in emergent biosolutions to acquire acam® business from sanofi july    et  source emergent biosolutions inc addition of acam® the only fdalicensed smallpox vaccine expands and diversifies emergent’s portfolio of medical countermeasures and is synergistic with company’s existing smallpox countermeasure offeringcompany to assume responsibility for existing cdc contract with a remaining value of up to approximately  million for deliveries of acam to the strategic national stockpileallcash consideration of  million upfront and up to  million in nearterm contingent regulatory and manufacturingrelated milestonestransaction expected to be accretive beginning with anticipated product deliveries in  following fda licensure of usbased manufacturing facility gaithersburg md july   globe newswire  emergent biosolutions inc nyseebs announced today that it has entered into an agreement to acquire the acam® smallpox vaccinia vaccine live business of sanofi in an allcash transaction with a total value of up to  million consisting of  million upfront and up to  million in nearterm contingent regulatory and manufacturingrelated milestones   upon the closing of this transaction emergent will acquire acam® smallpox vaccinia vaccine live the only vaccine licensed by the food and drug administration fda for active immunization against smallpox disease for persons determined to be at high risk for smallpox infectionan existing year contract originally valued at up to  million with the centers for disease control and prevention cdc with a remaining value of up to approximately  million for deliveries of acam to the strategic national stockpile snsa cgmp bulk manufacturing facility and a lease to a cgmp fillfinish facility both usbased along with the existing staff of approximately  employees daniel j abdunnabi president and chief executive officer of emergent biosolutions stated “this transaction diversifies our portfolio and broadens our countermeasure franchise with a vaccine that is being stockpiled both in the us and internationally we expect it to meaningfully contribute to revenue growth in  and advance our efforts towards achieving our goal of  billion in total revenue by  we further anticipate that acam will help us achieve our goal of generating more than  of total revenue from international markets this acquisition fits squarely within our core strategy and business focus and we look forward to closing this transaction and to integrating this business into our operations” strategic rationalethis transaction supports emergent’s plan to grow through the acquisition of revenuegenerating products and businesses leverages its core competencies in manufacturing and government contracting and reinforces the company’s strategic focus on providing preparedness solutions for public health threats the addition of acam expands the company’s portfolio of onlyinclass products diversifies its portfolio of medical countermeasures against category a bioterrorism agents and is synergistic with its existing smallpox countermeasure offering specifically vigiv vaccinia immune globulin intravenous human the only fdalicensed therapeutic for certain complications from smallpox vaccination upon the closing of the transaction emergent will assume responsibility for an existing year cdc contract which will expire and be up for renewal or extension in  the original contract valued at up to  million called for the delivery of acam to the sns and establishing usbased manufacturing of acam this required the tech transfer of the upstream portion of the production process from austria to a usbased manufacturing facility sanofi is in the process of completing this tech transfer to the cgmp bulk manufacturing facility to be acquired in this transaction emergent anticipates that a supplemental biologics license application for licensure of this facility will be filed in the second half of  upon closing emergent will assume all responsibilities under the cdc contract including completing the fda licensure process and the fulfillment of all remaining product deliveries to the sns valued at up to approximately  million subject to the availability of government funding and the exercise of contract options the company anticipates that product deliveries will resume in  following expected fda licensure of the usbased manufacturing facility the company expects that this transaction will be accretive beginning with product deliveries following fda licensure of the facility the company intends to negotiate a followon multiyear contract with the us government to ensure the continued supply of acam to the sns emergent expects that this transaction will enhance its contract manufacturing operations through the addition of live viral manufacturing and fillfinish capabilities and the execution of a contract manufacturing agreement to supply bulk drug substance for one of sanofi’s commercial vaccines this transaction which is subject to customary closing conditions including antitrust regulatory approval is expected to close in  cowen is acting as financial advisor to emergent in this transaction about acamacam is the primary smallpox vaccine designated for use in a bioterrorism emergency with more than  million doses having been supplied to the us strategic national stockpile acam is also licensed in australia and singapore and is currently stockpiled both in the us and internationally about smallpoxsmallpox is a highly contagious disease caused by the variola virus a member of the orthopox virus family according to the cdc it is one of the most devastating diseases with a mortality rate as high as  smallpox is classified by the cdc as a category a bioterrorism agent and the us government continues to invest in countermeasures to protect the nation from this threat governments around the world are also taking precautionary measures to be ready to deal with a potential smallpox outbreak conference call and webcastemergent will host a conference call to discuss this acquisition on july   at  am eastern the conference call will be accessible by dialing  and providing confirmation number  the call will also be webcast accessible from the company’s website at wwwemergentbiosolutionscom under “investors” a replay of the conference call will be accessible approximately one hour following the conclusion of the call by dialing  and using the passcode  the replay will be available through july   on the company’s website wwwemergentbiosolutionscom under “investors” about emergent biosolutionsemergent biosolutions inc is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental intentional and naturally emerging public health threats through our work we envision protecting and enhancing  million lives with our products by  additional information about the company may be found at emergentbiosolutionscom follow us emergentbiosolu safe harbor statementthis press release includes forwardlooking statements within the meaning of the private securities litigation reform act of  any statements other than statements of historical fact including statements regarding the expected closing of the transaction expected fda licensure of the us manufacturing facility for acam the anticipated delivery schedule under the existing cdc contract the potential opportunities and financial impact of the transaction and any other statements containing the words “believes” “expects” “anticipates” “intends” “plans” “targets” “forecasts” “estimates” and similar expressions are forwardlooking statements these forwardlooking statements are based on our current intentions beliefs and expectations regarding future events we cannot guarantee that any forwardlooking statement will be accurate investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize actual results could differ materially from our expectations investors are therefore cautioned not to place undue reliance on any forwardlooking statement any forwardlooking statement speaks only as of the date of this press release and except as required by law we do not undertake to update any forwardlooking statement to reflect new information events or circumstances there are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forwardlooking statements including uncertainties as to the satisfaction of closing conditions with respect to the transaction including the timing and receipt of thirdparty and regulatory approvals our ability to successfully integrate the business and realize the benefits of the transaction the timing of expected fda approval of the us manufacturing facility for acam our ability to extend or to otherwise deliver under the acam contract with the cdc upon its expiration in  the timing and yearly volume of product deliveries to the cdc once such deliveries have resumed under the current contract the availability of funding and the exercise of options under the current contract for acam and our ability to secure a followon multiyear contract with the cdc the foregoing sets forth many but not all of the factors that could cause actual results to differ from our expectations in any forwardlooking statement investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the sec when evaluating our forwardlooking statements investor contact robert g burrows vice president investor relations  burrowsrebsicom media contact lynn kieffer vice president corporate communications  kiefferlebsicom related articles other press releases by emergent biosolutions inc emergent biosolutions secures exclusive worldwide rights to valneva’s zika vaccine technology july    emergent biosolutions to release second quarter  financial results and conduct a conference call on august   july    emergent biosolutions to acquire raxibacumab an fdaapproved anthrax monoclonal antibody from gsk july    emergent biosolutions to hold annual meeting of stockholders thursday may   at  am edt webcast will be available may    emergent biosolutions unveils its expanded center for innovation in advanced development and manufacturing in baltimore may    profile emergent biosolutions inc   subscribe via rss  subscribe via atom  javascript gaithersburg maryland united states contact data investor contact robert g burrows vice president investor relations  burrowsrebsicom media contact lynn kieffer vice president corporate communications  kiefferlebsicom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files emergent biosolutions inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved emergent biosolutions  global specialty life sciences company skip to main content close menu close by using this site you agree to our privacy policy  close search toggle menu protecting you from public health threats our mission is to protect and enhance life watch our overview video emergent biosolutions prepare prevent protect we make medical countermeasures that address natural accidental and intentional public health threats our products target biological and chemical threats as well as emerging infectious diseases  strengthening our anthrax franchise emergent biosolutions to acquire raxibacumab from glaxosmithkline read the full press release expanding our portfolio of medical countermeasures emergent biosolutions to acquire acam vaccine business from sanofi read the full press release biothrax the only fda licensed anthrax vaccine hhs issues contract actions worth up to  billion in biothrax deliveries to the strategic national stockpile read the full press release nuthrax our next generation anthrax vaccine barda awards contract for advanced development and delivery of nuthrax valued at up to  billion read the full press release home explore more stories scroll down emergent biosolutions inc emergent biosolutions to acquire raxibacumab an fdaapproved anthrax monoclonal antibody from gsk  the wall street transcript register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsbuilding diversified portfolios with quality global equitiesbuilding accountability and avoiding mistakes through the decision processfinding optimal balance sheets by utilizing high yield market expertise analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today emergent biosolutions inc emergent biosolutions to acquire raxibacumab an fdaapproved anthrax monoclonal antibody from gsk tickers ebs allcash transaction includes a  million upfront payment and up to  million in product sale and manufacturingrelated milestone payments addition of licensed anthrax therapeutic expands emergents portfolio of approved medical countermeasures addressing public health threats emergent plans to assume responsibility for a multiyear contract with barda valued at up to approximately  million to supply raxibacumab to the sns bulk and fillfinish manufacturing expected to be transferred to existing emergent facilities located in baltimore maryland transaction expected to be accretive upon first product delivery under current barda contract anticipated within three to six months of closing gaithersburg md july   globe newswire  emergent biosolutions inc nyseebs announced today that it has entered into an agreement with gsk lsenyse gsk one of the worlds leading healthcare companies to acquire raxibacumab a fully human monoclonal antibody approved by the us food and drug administration fda for the treatment and prophylaxis of inhalational anthrax emergent also plans to assume responsibility for a multiyear contract with the biomedical advanced research and development authority barda valued at up to approximately  million to supply the product to the us strategic national stockpile sns the allcash transaction consists of a  million upfront payment and up to  million in product sale and manufacturingrelated milestone payments all of which would likely become due in  emergent expects to purchase product from gsk to fulfill deliveries to the sns under the current barda contract and plans to transfer raxibacumab manufacturing to existing emergent facilities in baltimore maryland in  daniel j abdunnabi president and chief executive officer of emergent biosolutions stated emergent is committed to continuing to build a portfolio of medical countermeasures that meets our customers needs to protect citizens from a broad array of public health threats the addition of this critical countermeasure further strengthens our leadership position in this market and expands our franchise of vaccines and therapeutics addressing category a bioterrorism threats we look forward to establishing raxibacumab as an anchor fdaapproved product for our newlyexpanded bayview manufacturing facility in baltimore maryland as we focus on providing preparedness solutions to public health threats we will continue to actively pursue additional acquisition opportunities that leverage our core competencies and drive growth top company interviews upon the closing of the transaction emergent will acquire raxibacumab including corresponding product rights regulatory approvals and intellectual property rights and plan to assume responsibility for an existing contract with barda a division of the office of the assistant secretary for preparedness and response at the us department of health and human services with a delivery order performance period through november  to supply raxibacumab to the sns with a remaining value of up to approximately  million emergent expects to fulfill the deliveries of raxibacumab to the sns by the end of  under the current barda contract subject to the availability of funding and expects to negotiate a followon contract with the us government to ensure the uninterrupted supply of this critical medical countermeasure to the sns under the terms of the acquisition agreements emergent expects to purchase product from gsk to enable completion of deliveries to the sns under the existing barda procurement contract in addition emergent intends to transfer all manufacturing related to raxibacumab to existing emergent facilities in  the company plans to transfer bulk manufacturing to its bayview facility also known as its center for innovation in advanced development and manufacturing where it is intended to serve as a commercial anchor product and the fillfinish process to its camden facility both facilities are located in baltimore maryland this transaction which is subject to customary closing conditions including antitrust regulatory clearance is anticipated to close in  the company expects that this transaction will be accretive upon first product delivery under the current barda contract which is anticipated within three to six months from closing cowen is acting as financial advisor to emergent in this transaction about raxibacumab raxibacumab is the first monoclonal antibody approved by the fda for the treatment and prophylaxis of inhalational anthrax due to bacillus anthracis it was approved in december  and has orphan drug designation in the us raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or not appropriate raxibacumab has been supplied to the sns since  under contracts with barda a division of the office of the assistant secretary for preparedness and response at the us department of health and human services conference call and webcast emergent will host a conference call to discuss this acquisition on july   at  pm eastern the conference call will be accessible by dialing  and providing confirmation number  the call will also be webcast accessible from the companys website at wwwemergentbiosolutionscom under investors a replay of the conference call will be accessible approximately one hour following the conclusion of the call by dialing  and using the passcode  the replay will be available through august   on the companys website wwwemergentbiosolutionscom under investors about emergent biosolutions emergent biosolutions inc is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental intentional and naturally emerging public health threats through our work we envision protecting and enhancing  million lives with our products by  additional information about the company may be found at emergentbiosolutionscom follow us emergentbiosolu safe harbor statement this press release includes forwardlooking statements within the meaning of the private securities litigation reform act of  any statements other than statements of historical fact including statements regarding the expected closing of the transaction the potential opportunities and financial impact of the transaction our plans to transfer the manufacturing and fillfinish processes to our bayview and camden facilities respectively and any other statements containing the words believes expects anticipates intends plans targets forecasts estimates and similar expressions are forwardlooking statements these forwardlooking statements are based on our current intentions beliefs and expectations regarding future events we cannot guarantee that any forwardlooking statement will be accurate investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize actual results could differ materially from our expectations investors are therefore cautioned not to place undue reliance on any forwardlooking statement any forwardlooking statement speaks only as of the date of this press release and except as required by law we do not undertake to update any forwardlooking statement to reflect new information events or circumstances there are a number of important factors that could cause the companys actual results to differ materially from those indicated by such forwardlooking statements including uncertainties as to the satisfaction of closing conditions with respect to the transaction such as the timing and receipt of antitrust regulatory clearance our ability to successfully integrate the assets and realize the benefits of the transaction the availability of funding and the placement of delivery orders under the current barda contract for raxibacumab the availability of funding and the us governments support of our plans for the transfer of the manufacturing and fillfinish processes to our bayview and camden facilities respectively and the timing thereof and our ability to secure a followon multiyear contract with the us government the foregoing sets forth many but not all of the factors that could cause actual results to differ from our expectations in any forwardlooking statement investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the sec when evaluating our forwardlooking statements acknowledgment of federal funding the aforementioned activities relating to raxibacumab have been funded in whole or in part with federal funds from the department of health and human services office of the assistant secretary for preparedness and response biomedical advanced research and development authority under contract numbers hhsoc and hhsoi investor contact robert g burrows vice president investor relations  burrowsrebsicom media contact lynn kieffer vice president corporate communications  kiefferlebsicom emergent biosolutions inc emergent biosolutions inc published this content on  july  and is solely responsible for the information contained herein distributed by public unedited and unaltered on  july   utc original documenthttpinvestorsemergentbiosolutionscomphoenixzhtmlcpirolnewsarticleid public permalinkhttpwwwpublicnowcomviewaaaecbdcabcbbede cartlatest newsall american usc footbal player joseph m boskovich jr now picks all american value stocks for his clientspaul hogan picks tech dividend growers microchip technology nasdaqmchp xilinx nasdaqxlnx and versum materials nysevsm gallons of water to produce a mcdonalds nysemcd quarter pounder how will investors profitthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsbuilding diversified portfolios with quality global equitiesgregory d padillaalberto jimenez crespo published july   in investing strategiescompanies covered amzn  aapl mu whr kimbera gs vod ppg shw viv pey buy building accountability and avoiding mistakes through the decision processdean pagonis published july   in investing strategiescompanies covered cmp sbh amzn ulta cvs lrlcy kmb www sdf buy finding optimal balance sheets by utilizing high yield market expertisezach miller published july   in investing strategiescompanies covered lsxmk siri bll chtr armk buy most popular reportsinvesting strategies published july  buy wireless communications  telecom published july  buy investing strategies published july  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsbuilding diversified portfolios with quality global equitiesbuilding accountability and avoiding mistakes through the decision processfinding optimal balance sheets by utilizing high yield market expertise analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google emergent biosolutions inc  product pipeline review   purchase this report emergent biosolutions inc  product pipeline review   published pages publisher report code mar   global markets direct asdr published mar      pages       publisher  global markets direct     report code  asdr descriptiondesc contentcont figures  tablesfiguresfig free samplesample emergent biosolutions inc  product pipeline review  summarythe new report emergent biosolutions inc  product pipeline review  ’ provides an overview of the emergent biosolutions inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by emergent biosolutions inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projectsthe new report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from the new report proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basisthe report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantagenote certain sections in the report may be removed or altered based on the availability and relevance of datascope the report provides a snapshot of the pipeline therapeutic landscape of emergent biosolutions inc the report provides overview of emergent biosolutions inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses emergent biosolutions inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features emergent biosolutions inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projectsreasons to buy evaluate emergent biosolutions inc’s strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for emergent biosolutions inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding emergent biosolutions inc’s pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope purchase this report us  euro € gbp £ user pdf us  site pdf us  enterprise pdf us  add to cart   lowest price guarantee license and delivery order process  question about this report this report can be of interest as well unisia amlodipine  candesartan  api insights  published july   report code asdr mark your calendar nd drug development forum  september   september boston united states  news releases  ebsi skip to main content close menucloseby using this site you agree to our privacy policy closesearchtoggle menuleadership news releaseswebcastq  emergent biosolutions inc earnings conference call live at  pm etkeyword search                        datetitle  emergent biosolutions secures exclusive worldwide rights to valneva’s zika vaccine technologyemergent biosolutions to release second quarter  financial results and conduct a conference call on august  emergent biosolutions to acquire raxibacumab an fdaapproved anthrax monoclonal antibody from gskemergent biosolutions to acquire acam® business from sanofiemergent biosolutions to hold annual meeting of stockholders thursday may   at  am edt webcast will be availableemergent biosolutions unveils its expanded center for innovation in advanced development and manufacturing in baltimoreemergent biosolutions to unveil its expanded center for innovation in advanced development and manufacturing supported through publicprivate partnership with bardaemergent biosolutions reports first quarter  financial results reaffirms  guidanceemergent biosolutions to release first quarter  financial results and conduct a conference call on may  emergent biosolutions signs  million modification to barda contract for the manufacture of botulism antitoxinemergent biosolutions awarded  million barda contract for biothrax deliveries to the strategic national stockpileemergent biosolutions reports fourth quarter and twelve months  financial results reaffirms  guidance and provides  goalsemergent biosolutions receives barda task order valued at up to  million to develop viral hemorrhagic fever therapeuticsemergent biosolutions to release fourth quarter and full year  financial results and conduct a conference call on february  emergent biosolutions initiates niaidfunded phase b clinical study to evaluate broadspectrum antiviral uvb for dengueemergent biosolutions receives german federal ministry of health approval of building  for largescale manufacturing of biothraxemergent biosolutions announces preliminary  financial results and provides  financial outlookinvestor toolkitprint pageemail pagerss feedsemail alertsfinancial tear sheetcorporate fact sheetonline investor kitinvestor faqsinformation requestfollow emergentbiosolu emergent biosolutions  global specialty life sciences company skip to main content close menu close by using this site you agree to our privacy policy  close search toggle menu protecting you from public health threats our mission is to protect and enhance life watch our overview video emergent biosolutions prepare prevent protect we make medical countermeasures that address natural accidental and intentional public health threats our products target biological and chemical threats as well as emerging infectious diseases  strengthening our anthrax franchise emergent biosolutions to acquire raxibacumab from glaxosmithkline read the full press release expanding our portfolio of medical countermeasures emergent biosolutions to acquire acam vaccine business from sanofi read the full press release biothrax the only fda licensed anthrax vaccine hhs issues contract actions worth up to  billion in biothrax deliveries to the strategic national stockpile read the full press release nuthrax our next generation anthrax vaccine barda awards contract for advanced development and delivery of nuthrax valued at up to  billion read the full press release home explore more stories scroll down